ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 07 4:00PM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
fuagf fuagf 23 seconds ago
Makes sense suicide would be more appealing to one believing they would get to a better place.
michael702/ michael702/ 59 seconds ago
style="font-size: 16px"BLLB and its Subsidiary Green Mantis LLC. has executed a MOU with strategic alliance to remediate Oil spillls in Nigeria Delta.
BLLB
Seminole Red Seminole Red 2 minutes ago
CVS removed images of all of its executives from the company's website following the killing of UnitedHealthcare CEO Brian Thompson on Wednesday in New York City.
CVS
mrfence mrfence 3 minutes ago
2016 Double Pop https://investorshub.advfn.com/uimage/uploads/2024/12/7/gnagwScreenshot_20241207_180009_Chrome.jpg
FNMA
ProfitScout ProfitScout 3 minutes ago
HNOI could get a lot of new attention from next week's upcoming exposure as mentioned in the company's latest news:

NEW YORK, Dec. 6, 2024 /PRNewswire/ -- Donald Owens, Chairman and CEO of HNO International (OTC: HNOI), a leader in green hydrogen innovation, will appear on the NASDAQ
HNOI
okwife okwife 3 minutes ago
when? not tonight?
XRPUSD
AKATITUS AKATITUS 3 minutes ago
Yup
Solid
Base
KULR
glenn1919 glenn1919 4 minutes ago
KITT.........VUZI...........MULN...................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
KITT MULN VUZI
Fred Kadiddlehopper Fred Kadiddlehopper 4 minutes ago
Correct, he was CEO before Helen Torley.
HALO
BDEZ BDEZ 4 minutes ago
Ukraine to get nearly $1 billion MORE for aid..WHUT!!!!!!!

https://x.com/bennyjohnson/status/1865545743676666237
3331 3331 5 minutes ago
BIEL: BUY RATING
https://www.barchart.com/stocks/quotes/BIEL/opinion
3331 3331 5 minutes ago
BIEL: BUY RATING
https://www.barchart.com/stocks/quotes/BIEL/opinion
okwife okwife 6 minutes ago
how high do you predict forw? i mean isn't this garbage?
the guy had all these years to make it ..
he is a scammer like all the rest here.
but he likes to call several others scammers
FORW
glenn1919 glenn1919 6 minutes ago
ATHE.......VUZI..........https://stockcharts.com/h-sc/ui?s=ATHE&p=D&yr=0&mn=2&dy=12&id=p84071410134
ATHE VUZI
fuagf fuagf 7 minutes ago
Olivia Troye reply to Patel threat to sue her

https://www.youtube.com/watch?v=bVGDRXxfUrI
Money4Nothing-M4N Money4Nothing-M4N 7 minutes ago
In defense of DH, you've got him confused with Dimes. Dimes was the one who mistook Safe Harbor for Calm Seas. Granted, the safest harbors do have calm seas.
KBLB
Adjustedtosteep Adjustedtosteep 8 minutes ago
They did not buy a public company and then invest 2 million dollars for nothing. They have pretty much gutted everything out of the public company reporting zero income. Now I believe they are incorporating the JV portion and the recurring revenue and that is what Movement will be going forward. The
MVNT
glenn1919 glenn1919 9 minutes ago
VUZI........................https://stockcharts.com/h-sc/ui?s=VUZI&p=W&b=5&g=0&id=p86431144783
VUZI
misterfishman misterfishman 9 minutes ago
Time will tell.
RDAR
BDEZ BDEZ 9 minutes ago
Millions are for sure, dropped out as they are disallusioned.
JoJr JoJr 9 minutes ago
If we keep going at a rate of 30% to 40% per day the RSI may not get over heated...
Sure there would be some days of consolidation... to be expected...
but I wouldn't want to risk flipping to get back in lower...
go ahead if you want to...
RDAR
misterfishman misterfishman 10 minutes ago
Yea wtf is wrong with that dude is said nothing to him but he come at me and accuse me like I know him or something simply amazing things some peeps make up in their head.
RDAR
glenn1919 glenn1919 13 minutes ago
ATHE.....VUZI......................https://stockcharts.com/h-sc/ui?s=ATHE&p=D&yr=0&mn=2&dy=12&id=p84071410134
ATHE VUZI
fuagf fuagf 14 minutes ago
I understood your point, and pretty much agreed with it. Trump's meeting with the three is understandable, and i made it clear what i saw as the basic needs of the three. Our common opinion that Trump is a grifter (a fraudster) seeking center-stage means nothing, but them meeting does recognize,

Your Recent History

Delayed Upgrade Clock